Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
All News
Article
Article
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.
Janet Pope
Tweet
The age old question in #inflammatory #arthritis
Should you cycle within TNFi class or move on to another MOA in
#PsA #psoriatic #arthritis
Better retention to go to a IL17i vs another TNFi in observational study comparing the 2
POS0266
#EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9
Janet Pope
Tweet
Can you predict which pts with
#PsA
#psoriatic #arthritis
Will respond to #TNFi #Rx?
Well, 🤔 maybe
Needs validation and an easy reliable inexpensive biomarker!
#EULAR2024 @RheumNow @eular_org
POS0992 https://t.co/Ce92561AMO
Aurelie Najm
Tweet
PsA: one composite index that does it all
cDAPSA + Investigator’s Global Assessment (IGA) of PSO
Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA
88% sensitivity & specificity in DISCOVER-1 & 2 trial data
#EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC
Aurelie Najm
Tweet
🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer
38 PSO patients w/ arthralgia
Correlation PET/CT SUVmax, TJC & tender enthesis count
68Ga-FAPI-04 uptake = higher risk developing PsA 6mo
Shows signs of inflammation before MSUS!
#EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn
Dr. Antoni Chan
Tweet
This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB
Did the patient fail on therapy or are the therapies failing the patient? 🤔
Difficult to to manage psoriatic arthritis: A suggested approach
#EULAR2024
NZ https://t.co/lYvXEX7dp3
New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated.
Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA
IH https://t.co/RvcONHCLvz
Aurelie Najm
Tweet
Swedish/Danish cohort study in PsA
17000+ bionaïve 8000+ TNFi & 2000+ other MoA
Overall non melanoma skin cancer rate 651
(505 BCC & 87 SCC)
TNFi treated pts:
HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50)
HR 1.19 NMSC vs. other MoA (ns)
#EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6
Aurelie Najm
Tweet
TYK2i RCT 290 pts 12 wks in active PSA
TAK-279 15mg 30 mg 53% 54% vs PBO 29%
ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15%
Safety profile acceptable
Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp
Dr. Antoni Chan
Tweet
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB
Dr. Antoni Chan
Tweet
Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793
Dr. Antoni Chan
Tweet
Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8
Dr. Antoni Chan
Tweet
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
Dr. Antoni Chan
Tweet
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU
Aurelie Najm
Tweet
200 millions pts PSO
1st line, Reduction risk PsA: IL 12-23 37% & IL-23 39% vs. TNFi
2nd line ttmt, IL12-23i 32% & IL-23i 31%
IL-23i 47% lower proba PsA than IL-17i 3 & 5 yrs
Can't exclude some channeling bias, but that's a big signal!
@RheumNow OP0010 #EULAR2024 #EULARBest
Dr. Antoni Chan
Tweet
A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb
💊 Difficult-to-treat #SpA & #PsA
🤔 What are the challenges in assessing persistently active disease?
🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease
🌎 Great to see #comorbidities highlighted
@RheumNow
#EULAR2024 https://t.co/x4jUTOC3li
Dr. Antoni Chan
Tweet
Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa
